# US 2026/0130854 A1 · Preparation of nano liniment for external treatment of gout

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0130854 A1
- Document ID: US20260130854A1
- Status: Published application
- Kind: A1
- Application number: 19/443,459
- Filed: 2026-01-08
- Published: 2026-05-14
- Earliest claimed: 2026-01-08
- Assignees: Boke ZHANG
- Inventors: Boke ZHANG
- Web page: https://patentgrep.com/patent/US20260130854A1

## CPC

- A61K 9/113: Multiple emulsions, e.g. oil-in-water-in-oil {(A61K9/0026 takes precedence)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/12: Ketones
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/415: 1,2-Diazoles
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A preparation method of an external nano liniment for gout is provided. The preparation method comprises the following steps: dissolving active ingredients into a water phase and/or an oil phase; adding a part of the water phase to a stirred oil phase to obtain hydrated oil phase nanoparticles; adding the hydrated oil phase nanoparticles to a part of the stirred water phase to obtain nanoparticles; and adding a cream phase to the stirred nanoparticles to obtain the nano liniment. The nanoparticles are of a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, active ingredients used for treating gout are embedded or dispersed in the water phase and/or the oil phase of the nanoparticles, and a size distribution of the nanoparticles is in a range of 1-200 nm.

## Claims

### Claim 1

A preparation method of an external nano liniment for gout, comprising:
(a) dissolving active ingredients into a water phase and/or an oil phase;
(b) adding a part of the water phase to a stirred oil phase to obtain hydrated oil phase nanoparticles;
(c) adding the hydrated oil phase nanoparticles to a part of the stirred water phase to obtain stirred nanoparticles; and
(d) adding a cream phase to the stirred nanoparticles to obtain the nano liniment.

### Claim 2 (depends on 1)

The preparation method of claim 1, wherein in (a), water-soluble active ingredients are dissolved in the water phase; fat-soluble active ingredients are added to the water phase and a pH of a solution is adjusted to 4-9, or ethanol (0.1-15 wt %) is added for solubilization; or the fat-soluble active ingredients are added to the oil phase to be heated for hydrotropy.

### Claim 3 (depends on 1)

The preparation method of claim 1, wherein in (a)-(d), a stirring speed is 10-5000 rpm, and a stirring temperature is 5-95° C.

### Claim 4 (depends on 1)

The preparation method of claim 1, wherein in (b), a weight ratio of the water phase to the hydrated oil phase is 1:1000-1:10, and the oil phase comprises an oil and a surfactant wherein a weight ratio of the oil to the surfactant is 10:1-1:10.

### Claim 5 (depends on 4)

The preparation method of claim 4, wherein in (b), the oil is caprylic capric triglyceride and/or medium chain triglyceride, and the surfactant is selected from one or more of PEG-40 hydrogenated castor oil, polyoxyethylated castor oil, polysorbate-20 and polysorbate-80.

### Claim 6 (depends on 1)

The preparation method of claim 1, wherein in (c), a weight ratio of the hydrated oil phase nanoparticles to the stirred nanoparticles is 1:1000-1:10.

### Claim 7 (depends on 1)

The preparation method of claim 1, wherein in (d), a weight ratio of the cream phase to the nano liniment is 1:1000-3:10.

### Claim 8 (depends on 1)

The preparation method of claim 1, wherein in (d), the cream phase is a home-made cream phase or Pemulen TR1, Pemulen TR2 or other cream phase emulsifiable pastes.

### Claim 9 (depends on 1)

A preparation method of a home-made cream phase for use in the preparation method of claim 1, comprising the following steps:
adding a water phase of the cream phase to water to stir and dissolve, and heating to 70-90° C.;
heating an oil phase of the cream phase to 70-90° C. to dissolve; and
slowly adding the oil phase of the cream phase to the water phase of the cream phase at a stirring speed of 1000-2000 rpm, stirring at a high speed of 1500-2000 rpm for 5-15 minutes, then reducing a speed to 400-800 rpm and cooling to 35-45° C., then adding an addition phase, cooling to room temperature, and stopping stirring.

### Claim 10 (depends on 9)

The preparation method of claim 9, wherein the water phase of the cream phase comprises the following components in parts by weight: 80-85 parts of water, 0.1-0.5 part of dipotassium glycyrrhizinate, 0.05-0.15 part of allantoin, 0.1-0.3 part of carbomer, 0.5-1.5 parts of nicotinamide, 0.01-0.05 part of sodium hyaluronate, 0.05-0.15 part of methylparaben, 2-4 parts of glycerol, 2-4 parts of propylene glycol and 2-4 parts of butanediol.

### Claim 11 (depends on 9)

The preparation method of claim 9, wherein the oil phase of the cream phase comprises the following components in parts by weight: 1-3 parts of cetostearyl alcohol, 0.3-0.7 part of PEG-100 stearate, 0.3-0.7 part of glyceryl stearate, 0.3-0.7 part of polydimethylsiloxane, 2-4 parts of caprylic capric triglyceride, 0.1-0.3 part of stearic acid, 0.6-1.0 part of mineral oil, 0.3-0.5 part of propyl hydroxybenzoate, 0.3-0.7 part of avocado oil, 0.3-0.7 part of jojoba oil and 0.3-0.7 part of evening primrose oil.

### Claim 12 (depends on 9)

The preparation method of claim 9, wherein the addition phase comprises the following components in parts by weight: 0.1-0.3 part of triethanolamine, 0.4-0.8 part of phenoxyethanol and 0.05-0.15 part of essence.

### Claim 13 (depends on 9)

The preparation method of claim 9, wherein the home-made cream phase provides protection and long-term stabilization effects on the stirred nanoparticles and assists the nano liniment to realize transdermal absorption.

### Claim 14 (depends on 1)

The preparation method of claim 1, wherein the active ingredients comprise at least one of 4-hydroxymethyl phenyl-beta-D-glucopyranoside, febuxostat, allopurinol, benzbromarone, colchicine, topiroxostat, lesinurad, etoricoxib, meloxicam, diclofenac sodium, diclofenac potassium, probenecid, indometacin, ibuprofen, loxoprofen, piroxicam, celecoxib, dexketoprofen trometamol, acetohexamide, camphor, borneol and mint.

### Claim 15 (depends on 1)

The preparation method of claim 1, wherein a single active ingredient of the active ingredients is in a content of 0.01-10% with respect to a total weight of the nano liniment.

### Claim 16 (depends on 1)

The preparation method of claim 1, wherein the stirred nanoparticles have a particle size distribution in a range of 1-200 nm.

### Claim 17 (depends on 16)

The preparation method of claim 16, wherein the stirred nanoparticles have a particle size distribution in a range of 1-100 nm.

### Claim 18 (depends on 17)

The preparation method of claim 17, wherein the stirred nanoparticles have a particle size distribution in a range of 1-50 nm.

### Claim 19 (depends on 1)

The preparation method of claim 1, wherein when the active ingredients are a single active ingredient, a content of the active ingredients is 0.1-10% with respect to the total weight of the nano liniment, and when the active ingredients are multiple active ingredients, a sum content of the different active ingredients is 0.4-10% with respect to the total weight of the nano liniment.

### Claim 20 (depends on 1)

The preparation method of claim 1, wherein the stirred nanoparticles are of a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, and the active ingredients are embedded or dispersed in the water phase and/or the oil phase of the stirred nanoparticles.
